Sales Through Retail Pharmacies (Twelve months to July 2011)*
U.S.A. $228.5 billion up 3%
JAPAN (including hospitals) $94.1 billion up 4%
CHINA (hospital) $36.3 billion up 18%
GERMANY $37.8 billion up 4%
FRANCE $28.9 billion no movement
BRAZIL $20.5 billion up 19%
CANADA $19.7 billion down 2%
ITALY $16.3 billion no movement
SPAIN $14.5 billion down 3%
UK $14.1 billion up 1%
AUSTRALIA/NZ $10.9 billion up 6%
MEXICO $8.1 billion up 2%
VENEZUELA $5.5 billion up 31%
ARGENTINA $4.6 billion up 30%
****************
The top 5 therapy classes at ATC3 level in the 12 months to July 2011 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B - Antiulcerants
3. N5A - Antipsychotics
4. N6A – Antidepressants & mood stabilisers
5. C9C – Angioten-II Antag, Plain
The top 5 products in the 12 months to July 2011 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor
The top 5 corporations in the 12 months to July 2011 were:
1. Pfizer
2. Novartis
3. AstraZeneca
4. Merck & Co
5. GlaxoSmithKline